$PNT entry PTs 1-4 Target PT 65 and higherDescription: POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radiolig
0%
0%
0%
0%
0%